[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599145":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":37,"collaborators":26,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":26,"enrollmentInfo":50,"targetDuration":26,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":26,"overallStatus":59,"whyStopped":26,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":26},{"fullName":5,"class":6},"University of Messina","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Short DAPT with Ticagrelor 60 mg","EXPERIMENTAL","* 1-month DAPT: aspirin + ticagrelor 60 mg BID\n* Followed by 5-month ticagrelor 60 mg BID monotherapy\n* Ticagrelor will be provided by the sponsor (off-label use)",[13],"Drug: Ticagrelor 60 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard DAPT with Clopidogrel","ACTIVE_COMPARATOR","\\- 6-month DAPT: aspirin + clopidogrel 75 mg daily",[19],"Drug: clopidogrel 75 mg",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ticagrelor 60 mg","Patients in this arm will receive dual antiplatelet therapy (DAPT) consisting of low-dose ticagrelor (60 mg twice daily) plus aspirin (75-100 mg once daily) for 1 month, followed by ticagrelor 60 mg monotherapy for 5 additional months (total 6 months of therapy).\n\nThis strategy aims to reduce ischemic events while minimizing bleeding risk by leveraging the potent antiplatelet effect of ticagrelor at a lower maintenance dose.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"clopidogrel 75 mg","Patients in the control group will receive standard DAPT consisting of clopidogrel 75 mg once daily plus aspirin 75-100 mg once daily for 6 months.\n\nThis represents the current standard of care in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Rodolfo Caminiti","CONTACT","+393286911102","rodolfocaminiti@msn.com",{"type":38,"investigatorFullName":33,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Principal Investigator, Interventional Cardiologist","100599145","phase-4-short-term-dual-antiplatelet-therapy-with-early-transi-tion-to-low-dose-antiplatelet-monotherapy-using-ti-cagrelor-in-chronic-coronary-artery-disease-100599145",false,"NCT07080684","Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","Short-Term Dual Antiplatelet Therapy With Early Transition to Low-dose Antiplatelet Monotherapy Using ticagRelor in Chronic Coronary Artery Disease","STELAR","Inclusion Criteria:\n\n* Age ≥18 years at the time of informed consent.\n* Diagnosis of chronic coronary syndrome (CCS) according to ESC guidelines.\n* Undergoing successful PCI with implantation of one or more new-generation drug-eluting stents (DES).\n* Indication for dual antiplatelet therapy (DAPT) following PCI.\n* Willingness and ability to comply with all study procedures and follow-up assessments.\n* Signed informed consent prior to any study-specific procedure.\n* Creatinine clearance ≥30 mL\u002Fmin, calculated using the Cockcroft-Gault formula.\n* Life expectancy greater than 1 year in the investigator's judg-ment.\n* Hemodynamically stable at the time of randomization.\n* Acceptable bleeding risk profile: patients fulfilling ARC-HBR criteria may be included only if the treating physician deems a 6-month antiplatelet regimen to be safe.\n* No contraindications to study drugs, including aspirin, clopi-dogrel, or ticagrelor.\n\nExclusion Criteria:\n\n* Presentation with acute coronary syndrome (ACS), including STEMI, NSTEMI, or unstable angina within the previous 6 mon-ths.\n* Planned staged PCI or revascularization procedure within 6 months after index PCI.\n* Requirement for long-term oral anticoagulation therapy, such as for atrial fibrillation, mechanical heart valves, or venous thromboembolism.\n* History of major bleeding, including gastrointestinal or intra-cranial bleeding, within the past 6 months.\n* Severe hepatic impairment, active liver disease, or transamina-ses \\>3× upper limit of normal.\n* Known platelet disorder, coagulopathy, or thrombocytopenia (\\\u003C100,000\u002Fmm³).\n* Contraindication or hypersensitivity to aspirin, clopidogrel, or ticagrelor, or known drug interaction that precludes their use.\n* Ongoing active bleeding or high risk of bleeding that, in the opinion of the investigator, precludes DAPT.\n* Pregnancy or breastfeeding, or women of childbearing potential who are not using effective contraception.\n* Life expectancy \\\u003C1 year due to non-cardiovascular comorbidi-ties (e.g., cancer, advanced renal failure).\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.\n* Severe anemia (hemoglobin \\\u003C9 g\u002FdL) not corrected before ran-domization.\n* Inability or unwillingness to provide informed consent or ad-here to study follow-up.\n* Prior stroke with residual neurological deficit or history of di-sabling stroke (mRS ≥3).","ALL","18 Years",{"count":51,"type":52},1000,"ESTIMATED","INTERVENTIONAL",[55],"PHASE4","This is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication (PROBE design), comparing one-month dual antiplatelet therapy (DAPT) with low-dose ticagrelor (60 mg BID) followed by ticagrelor monotherapy to standard 6-month DAPT with aspirin and clopidogrel in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI). The primary endpoint is a composite of cardiovascular death, all-cause death, myocardial infarction, disabling stroke, target lesion revascularization (TLR), and major bleeding. The study aims to evaluate whether the short DAPT strategy reduces ischemic events while maintaining bleeding safety.",[58],"Chronic Coronary Syndrome","NOT_YET_RECRUITING","2025-07-14",{"date":62,"type":63},"2025-07-23","ACTUAL",{"date":65,"type":52},"2025-12-01",{"date":67,"type":52},"2027-09",{"name":5,"class":6}]